By now, you’ve probably heard about FTC efforts to ban reverse-payment patent settlements. FTC chairman Jon Leibowitz claims pharma-generic company deals are among “the most corrupt practices in healthcare today,” asserting settlements prevent cheaper generic drugs from entering the market sooner, delaying savings to consumers.
When Paul Thacker announced in July that he was leaving the Senate Finance Committee, you could practically hear drug company lobbyists whooping for joy.
Something good’s going on. Professional journal advertising has rebounded in spectacular fashion in the first-half 2010. James Chase reports on the biggest advertisers and most advertised brands
Leadership Exchange: How Do You Measure Patient Programs?
The Board of the Accreditation Council for CME approved a new process for handling complaints on accredited providers, in which those that break the rules will not be identified unless changes in their accreditation status occur.
Is Grassley’s ghostwriting report still relevant?
September 15, 2010
5:33 pm
Sen. Chuck Grassley released a report shedding light on the controversial practice of ghostwriting. Some say his findings are based on outdated publication-planning practices. How should we put Sen. Grassley’s report in context?
Social media provided unheard early warning on Avandia
A new report whose findings could have profound implications for adverse events reporting says patients began discussing the risks of GlaxoSmithKline diabetes drug Avandia in online forums and blogs well before a meta-analysis linked it to higher heart-attack risk.
Last month, I began this column by revealing what seemed like the first piece of good news in a long time–namely, that the average paycheck in the industry had risen for the first time in three years, according to our Career & Salary Survey.